I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| natural killer cell | 7 studies | 19% ± 3% | |
| CD16-positive, CD56-dim natural killer cell, human | 6 studies | 17% ± 2% | |
| epithelial cell | 6 studies | 31% ± 13% | |
| endothelial cell | 5 studies | 24% ± 5% | |
| CD16-negative, CD56-bright natural killer cell, human | 4 studies | 18% ± 3% | |
| CD4-positive, alpha-beta T cell | 4 studies | 18% ± 2% | |
| B cell | 4 studies | 16% ± 2% | |
| fibroblast | 4 studies | 24% ± 5% | |
| ciliated cell | 4 studies | 28% ± 5% | |
| CD8-positive, alpha-beta T cell | 4 studies | 19% ± 3% | |
| naive B cell | 3 studies | 16% ± 1% | |
| pericyte | 3 studies | 17% ± 1% | |
| amacrine cell | 3 studies | 34% ± 9% | |
| abnormal cell | 3 studies | 24% ± 6% | |
| CD8-positive, alpha-beta memory T cell | 3 studies | 18% ± 3% | |
| GABAergic neuron | 3 studies | 29% ± 3% | |
| glutamatergic neuron | 3 studies | 38% ± 7% | |
| dendritic cell | 3 studies | 25% ± 7% | |
| gamma-delta T cell | 3 studies | 27% ± 16% |
